63339-68-4
Chemical Structure
Chuangxinmycin
- CAS No.: 63339-68-4
- Formula:C12H11NO2S
- Molecular Weight:233.29
InChIKey: DKHFLDXCKWDVMF-UPONEAKYSA-N
SMILES: C[C@H]1C2=CNC3=CC=CC(S[C@H]1C(O)=O)=C23
Biological Activity: Chuangxinmycin is a tryptophanyl-tRNA synthetase inhibitor. Chuangxinmycin blocks protein synthesis by competitively binding to the tryptophan/ATP pocket of bacterial TrpRS, exhibits broad-spectrum antibacterial activity against Gram-positive and Gram-negative bacteria, and shows antimycobacterial activity against susceptible, drug-resistant, and intracellular M. tuberculosis. Chuangxinmycin induces PTC readthrough and restores full-length Collagenase, Type VII (HY-E70005J), and can be used for research on tuberculosis, RDEB, and Escherichia coli/Shigella dysenteriae infections[1][2][3][4][5][6][7][8].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Chuangxinmycin | Chuangxinmycin is a tryptophanyl-tRNA synthetase inhibitor. Chuangxinmycin blocks protein synthesis by competitively binding to the tryptophan/ATP pocket of bacterial TrpRS, exhibits broad-spectrum antibacterial activity against Gram-positive and Gram-negative bacteria, and shows antimycobacterial activity against susceptible, drug-resistant, and intracellular M. tuberculosis. Chuangxinmycin induces PTC readthrough and restores full-length Collagenase, Type VII (HY-E70005J), and can be used for research on tuberculosis, RDEB, and Escherichia coli/Shigella dysenteriae infections. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Kozikowski AP, et al. Synthetic studies in the indole series. Preparation of the unique antibiotic alkaloid chuangxinmycin by a nitro group displacement reaction. Journal of the American Chemical Society. 1982 Dec;104(26):7622-6.
- [2]. Jover I, et al. Identification of novel small molecule-based strategies of COL7A1 upregulation and readthrough activity for the treatment of recessive dystrophic epidermolysis bullosa. Scientific reports. 2024 Aug 16;14(1):18969. [Content Brief]
- [3]. Sun L, et al. Synthesis, resolution, derivatization and antibacterial activity of chuangxinmycin. Future medicinal chemistry. 2019 Nov;11(22):2877-2890.
- [4]. Brown MJ, et al. The antimicrobial natural product chuangxinmycin and some synthetic analogues are potent and selective inhibitors of bacterial tryptophanyl tRNA synthetase. Bioorganic & medicinal chemistry letters. 2002 Nov 04;12(21):3171-4.
- [5]. Han X, et al. Selective Inhibition Mechanism of Mycobacterium tuberculosis Tryptophan-tRNA Synthetase by Chuangxinmycin. ACS Infectious Diseases. 2025 May 15;11(6):1577-88.
- [6]. Fan S, et al. Structural insights into the specific interaction between Geobacillus stearothermophilus tryptophanyl-tRNA synthetase and antimicrobial Chuangxinmycin. The Journal of biological chemistry. 2022 Feb;298(2):101580.
- [7]. Zhao X, et al. Targeted high-level production of chuangxinmycin and its halogenated derivatives with antitubercular activity. Microbial cell factories. 2025 May 19;24(1):113.
- [8]. Ren Y, et al. Mechanistic insights into the ATP-mediated and species-dependent inhibition of TrpRS by chuangxinmycin. RSC chemical biology. 2025 Jul 02;6(7):1079-1088.
